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Introduction: Some providers report concern for the safety of transgender hormone therapy (HT).
Methods: This is a systematic literature review of HT safety for transgender adults.
Results: Current literature suggests HT is safe when followed carefully for certain risks. The greatest
health concern for HT in transgender women is venous thromboembolism. HT among transgender men
appears to cause polycythemia. Both groups experienced elevated fasting glucose. There is no increase in
cancer prevalence or mortality due to transgender HT.
Conclusion: Although current data support the safety of transgender HT with physician supervision,
larger, long-term studies are needed in transgender medicine.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Access to healthcare for transgender individuals is limited, and
some providers report concern for the safety of hormone therapy
(HT) for transgender individuals [1]. This review article seeks to
provide an overview of current knowledge in transgender medicine
as it relates to the safety of hormone therapy (HT) for transgender
adults. A severe limitation in this ﬁeld is the lack of large-cohort
studies to study the long-term effects of hormone therapy [1].
Current guidelines and medical knowledge provided in this review
are the result of a small number of studies; the studies with the
greatest statistical power are listed ﬁrst in each section. Much of the
existing data on transgender HT are from case reports, however
these provide less reliable insight into the association of HT and
long-term health outcomes. Case reports are provided for the
completeness of this review and due to the limitations of this ﬁeld,
however these are listed last.l interests exist.
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This literature review was conducted searching the terms
“transgender” and “transsexual” on the electronic PubMed data-
base by a single author over March 9e12, 2014, which retrieved
1881 articles from 1967 to 2014. Articles that had a primary
research project or literature review designed to assess some
aspect of the safety of hormone therapy for transgender individuals
were considered, as well as papers from select bibliographies, to
clarify existing limited knowledge on topics in hormone therapy for
which there is limited to no research among transgender in-
dividuals on HT. Case reports were used when other long-term
studies were not available, which is a signiﬁcant limitation in this
ﬁeld. Where not otherwise mentioned, study controls are non-
transgender individuals, who are not on hormone therapy, and
study participants are transgender individuals who either are
initiating or continuing HT.Cardiovascular proﬁle
Venous thrombosis events may be estrogen related and therefore
a concern for MTF transgender individuals
The greatest concern among male-to-female (MTF) transgender
individuals is the potential increase in thromboembolic eventsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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date, Asscheman et al. (2014), observed the lowest reported rate of
1% of adults experiencing VTE among 1076 MTF individuals for an
average follow of 5.4 years [2]. Other compelling data suggest that
the incidence of venous thromboembolism (VTE) among trans-
gender women appears associated with the presence of a hyper-
coaguable risk factor, including the use of an especially
thrombogenic estrogen (ethinyl estradiol) which is no longer used
[3]. Gooren et al. (2008), reported no increase in VTE among 2236
male-to-female (MTF) transgender individuals on HT from 1975 to
2006 comparedwith controls, with the exception of thosewho used
ethinyl estradiol, for which there was a 6e8% incidence [4]. Addi-
tionally, while Wierckx et al. (2013) observed 5% of 214 MTF in-
dividuals to have a VTE within the ﬁrst three years of estrogen
therapy, 10 out of 11 of these women had at least one VTE risk factor
such as smoking, immobilization due to gender conﬁrmation sur-
gery, or a hypercoaguable disorder [5]. Wierckx et al. (2012), previ-
ously found a 6% incidence of VTE among transgender women
(n¼ 50) after an average of 11.3 years on HT, and released with their
data a recommendation to discontinue estrogen therapy aminimum
of 2 weeks minimum prior to any surgery, coupled with increased
mobility after the surgery, to minimize this VTE risk factor [6]. The
incidence of VTE events among transgender men did not change
compared to female andmale controls in these studies in Asscheman
et al. (2014) (n ¼ 523 study participants), Gooren et al. (2008)
(n ¼ 876), Wierckx et al. (2013) (n ¼ 138) and Wierckx et al. (2012)
(n ¼ 79) [2,4e6].
Venous thrombosis events (VTE) were reported in MTF in-
dividuals as early as 1976, when a 29-year old transgender woman
with no history or risk factors for VTE presented with pulmonary
embolism after beginning estrogen therapy of diethylstilbestrol
(DES) [7]. A 1978 paper also observed an occlusion of the middle
cerebral artery during estrogen therapy in a transgender woman,
where the patient was reported using mestranol, a 3-methyl ether
of ethinyl estradiol [8].
Elevated cerebrovascular disease and myocardial infarctions for MTF
individuals
Similar to the previous reports of VTE events among MTF in-
dividuals on estrogen therapy, data suggest that transgender
women may have an elevated risk of vascular events compared to
female controls. Wierckx et al. (2013) (n ¼ 214) reported an inci-
dence of MI among MTF adults that matched that of male controls,
but exceeded female controls; three transgender women experi-
enced a myocardial infarction (average 48 years old) within two
years of estrogen therapy [5]. In the same study, an increase in
cerebrovascular disease and transient ischemic attack (TIA) among
MTF adults was also observed in the same study, as compared to
male controls; ﬁve transgender women on estrogen therapy
(average 7.2 years) experienced one of these conditions (average
51 years old).
Wierckx et al. (2012) also examined 100 transgender men and
women and found that 6% of transgenderwomen had cardiovascular
health problems after an average of 11.3 years on estrogen ther-
apy [6]. These included 2 reports of MI, 1 report of TIA, and 1 case of
venous ulcer where ethinyl estradiol was used. The other two cases
were suggested to be less related to the individual’s estrogen ther-
apy, including peripheral arterial disease due to complications of
diabetes and a MI before HT. Futhermore, 5 out of 6 of these trans-
gender women smoked for an average of 24 years, and the authors
suggested that both smoking risk and the known role of estrogen
hormone replacement therapy in increased risk TIA and VTE might
play a role in these cases. Such a role has been outlined in previous
literature [9].The rates of CVD/TIA and MI among transgender men did not
change compared to male controls in the above studies of Wierckx
et al. (2013) (n ¼ 138) and Wierckx et al. (2012) (n ¼ 79) [2e6].
VTE risk may be lessened by use of transdermal estrogen in MTF
adults
The “ﬁrst-pass” hypothesis of liver metabolism of estrogen
proposes that there is a decrease of thromboembolic and other
cardiovascular events with the use transdermal as opposed to oral
estrogen therapy [10e12]. In Ott et al. (2010), 162 transgender
women were followed for a mean of 64.2 months, and there were
no reports of VTE while using transdermal 17b estradiol [13]. Wil-
son et al. (2009) also observed increases in inﬂammatory markers
(cytokine IL-6, IL-1 and IL-8, clotting factors FV11 and FVIX and
superoxide dismutase) consistent with this hypothesis for MTF
individuals taking oral estrogen, but not for those taking trans-
dermal estrogen [14].
The rates of VTE among transgender men did not change
compared to male controls in the above studies of Ott et al. (2010)
(n ¼ 89) [13].
Estrogen therapy may be safe even for MTF adults who have
hypercoagulable mutations
Estrogen therapy in transgender adults may be safe even in the
presence of hypercoaguable gene deﬁciencies. In Ott et al. (2010),
no VTE events were reported among the same 162 MTF and 89 FTM
individuals followed, despite observation of activated protein
C resistance and deﬁciency in 7% and 4%, respectively [13].
The effects of other clotting related gene mutations in
conjunction with estrogen therapy in transgender adults have not
been as well studied. One case report noted that an MTF individual
who experienced a myocardial infarction and VTE on heparin was
deﬁcient in antithrombin III, and that this individual’s deﬁciency
was corrected when HT was stopped [15].
Isolated case studies of cardiovascular incidents among transgender
adults are inconclusive
There are four case reports of sudden death of transgender in-
dividuals on estrogen therapy since 1988, however the isolated
nature of these case studies provides little conclusive evidence of
the likelihood of the link between estrogen and these conditions.
These reports include the earliest case of the death of a 22 year old
MTF transgender individual by arrhythmogenic right ventricular
dysplasia [16], along with complications in previously healthy MTF
individuals: VTE, atherosclerosis, and syncope [17,18]. There are also
two reports in the literature of idiopathic intracranial hypertension
(IIH) among transgender men after initiating HT [19,20].
Individual case reports among FTM individuals are also incon-
clusive, and include a 32 year old FTM individual on testosterone
therapy who died suddenly after two years from ischemic heart
disease as a result of coronary stenosis [21].
Oncology
No increase in cancer prevalence among transgender individuals
on HT
While some guidelines for transgender medical care express
concerns for elevated cancer risk with certain hormone regimes,
current data suggest that the risk of cancer may not rise.
Although studies are small, overall cancer incidence in trans-
gender men and transgender women to-date has not been found
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There are no reports of change in breast cancer speciﬁc risk among
transgender individuals on estrogen compared to secular trends of
male breast cancer incidence. Rates are lower relative to secular
trends of female breast cancer rates. Gooren et al. (2013) reported
that among 795 FTM individuals there was a breast cancer rate of
5.9 cases per 100,000 person-years and of 4.1 cases per 100,000
person-years among 2307MTF persons [22]. In Kuroda et al. (2008),
no breast carcinoma was found among FTM individuals (n ¼ 56)
who had been on estrogen for an average of 11 months, while one
breast carcinoma was found in among those FTM individuals
(n ¼ 130) who were not on estrogen [23].
Rather than elevated cancer risk, studies such as Miller et al.
(1986) (n ¼ 32) and Perrone et al. (2009) (n ¼ 30) suggest that the
result of testosterone therapy in FTM individuals is tissue atrophy of
the epithelium of the cervix [24] and endometrium [24,25], with
maintenance of corpus luteum in ovaries even after one year of
therapy [24]. Gardner et al. (2014), observed that in surgical
endometrium tissues obtained from 15 FTM there was no increase
in either the genes related to endometrial proliferation or endo-
metrial malignancy [25]. Estrogen receptors (ERa and ERb) were
also observed in another study (n ¼ 16) to decrease in the vaginal
epithelium of transgender men [26].
There are reports of hyperplasia in female reproductive tract
tissues of FTM individuals on testosterone therapy however these
studies are lower powered. In an English-language abstract of the
Russian-language paper by Mikhaĭlichenko et al. (2013), it was re-
ported that hormone therapy resulted in hyperplasia of female
reproductive tract and breast tissues among FTM individuals,
as well as metaplasia in prostate tissue in MTF individuals [27].
Similar results were reported in Ikeda et al. 2013 who suggested
that among FTM individuals (n ¼ 11) on testosterone, hyperplasia
increased in the ovarian stroma and the ovarian cortex was thick-
ened [28].
There are several case reports of prostate cancer in transgender
women [29,30]. A comprehensive study among the medical records
of 2306 orchidectomized MTF individuals reported an overall rare
but possible incidence of prostate cancer of 0.04%, limited by
decreased screening and younger average age of 29.3 among these
individuals at the start of therapy [31].
Additionally, there are ten case reports of breast cancer devel-
opment amongMTF individuals on estrogen since 1968 [23,32e37].
Similarly, within the last 50 years only 4 cases of breast cancer in
FTM individuals have been recorded [38]. Pseudoangiomatous
stromal hyperplasia, the condition of a rare benign breast connec-
tive tissue lesion found typically only in women and men with
gynecomastia, was encountered among 2 FTM individuals [39].
Uterine and invasive cervical cancer was reported in one FTM in-
dividual [40].
There are three case reports of MTF individuals with meningi-
oma while on estrogen HT involving intracranial [41], tuberculum
sellae [42], and an olfactory groove locations [43], and one case
report of a pituitary adenoma [44]. There are no reports in the
literature of any of the following estrogen-related growth factor
tumors: hemangioma, angiomyolipoma, or focal nodular
hyperplasia.
Mortality
No direct increase in mortality due to HT in transgender adults
The three largest studies to date on mortality and transgender
hormone therapy suggest no direct increased risk in mortality.
A large study in 15 different centers of over 2000 transgender
adults found no increase in mortality compared to controls [2].Gooren et al. (2008) monitored 2236 MTF and 876 FTM individuals
on HT and observed no change compared to controls [3]. Assche-
man et al. (2011) reported that over an average of 18.5 years among
966 MTF and 365 FTM individuals, MTF did have a 51% increase in
mortality compared to secular data [45]. However, these differences
were attributable to outside causes such as the increased incidence
of suicide, AIDS, substance abuse and cardiovascular disease;
notably there was also no increase in cancer mortality among these
individuals. The authors found no increase in mortality of FTM
individuals.
Laboratory values
Changes in triglycerides and cholesterol with MTF HT; inconclusive
changes among FTM HT
Roberts et al. (2013) (n ¼ 55) reported elevated median tri-
glyceride levels of 120 mg/dL among MTF adults compared to both
male (80 mg/dL median) and female (60 mg/dL median) control
groups, with the range of participant values spanning from 34.2 to
242.6 mg/dL [46]. Cholesterol (LDL) levels among MTF individuals
resembled female controls. In Jacobeit et al. (2009), transgender
men (n ¼ 17) monitored for a 3 year period observed decreases in
plasma cholesterol, decreases in LDL and no change in HDL [47].
Meyer et al. (1986) reported no signiﬁcant changes among MTF
individuals (n ¼ 18) in triglycerides or total cholesterol, and among
FTM individuals (n ¼ 14) there were reported small increases in
triglycerides and total cholesterol to the upper limit of normal of
female controls [48]. The study authors also observed that among
subjects, plasma cholesterol and triglycerides rose with an increase
in testosterone dose.
Hematocrit and hemoglobin; increases among FTM individuals,
no change in transgender women
Jacobeit et al. (2009) also observed that among FTM individuals
on testosterone therapy, hematocrit and hemoglobin increased as
compared to controls but were within normal ranges [49]. Roberts
et al. (2013) reported that for MTF adults on estrogen therapy the
values of hemoglobin and hematocrit were similar to female
controls [48].
Liver function tests; no change on HT in transgender adults
In Roberts et al, 2013 among MTF individuals, alkaline phos-
phatase, potassium and creatinine values resembled male controls
[48]. Liver enzymes did not change appreciably among FTM adults
as reported by Jacobeit et al. (2009) [49]. Hampl et al. (1986)
observed that among 6 transgender men on HT for 3 months there
was no decrease in liver function [49].
BUN and creatinine; MTF levels similar to male controls
Roberts et al. (2013) reported no difference in blood urea
nitrogen values among the same 55 MTF adults compared to both
male and female control groups and no difference in creatinine
values compared to non-transgender male controls [48].
Uric acid; estrogen may elevate uric acid excretion with MTF HT
Yahyaoui et al. (2008) found that fractional excreted of uric acids
(FEUC) levels increased among 22 MTF individuals and decreased
among 47 FTM individuals after two years of HT, supporting
their hypothesis of increased fractional excretion of uric acid (FEUA)
with rising estrogen [50]. Uric acid levels decreased in the MTF
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greater excretion, and increased among the FTM individuals
compared to their baseline due to less excretion. The study authors
found no clear link between testosterone and FEUA.
Glycemia, metabolism and insulin sensitivity
Worsened glycemic metabolism for transgender adults on HT
Most studies on glycemic control in transgender individuals on
HT report increased insulin resistance and fasting glucose.
Wierckx et al. (2013) observed an increased in type 2 diabetes
among both FTM and MTF individuals [5]. Gooren et al. (2008)
reported decreased insulin sensitivity among both MTF and FTM
individuals on HT, as well as elevated fasting insulin on MTF HT [4].
Bosinski et al. (1997) reported a higher rate of PCOS and non-
classical congenital adrenal hyperplasia among 12 FTM in-
dividuals prior to HT, suggesting a pre-existing metabolic risk in
this population [51]. Whether these metabolic parameters relate to
hormone therapy or simply a general response to change in body
hormones remains to be studied. Polderman et al. (1994) studied
glycemic control of 18 MTF and 13 FTM individuals using a glucose-
clamp technique whose results also suggested that HT in both
groups could increase insulin resistance [52]. A lower powered
1986 study of 6 FTM individuals reported no change for these adults
on HT in respect to with insulin sensitivity [51].
Only small studies are available for leptin, adiponectin, and
ghrelin. Transgender men had decreased adiponectin levels while
transgender women had decreased leptin [53]. Prior animal studies
have reported that both are associated with insulin resistance, and
that adiponectin may have a protective effect against elevated tri-
glycerides [54]. Among 15 MTF non-diabetic individuals in Resmini
et al. (2008), MTF individuals had leptin levels lower than female
controls and higher than male controls [53]. Adiponectin was also
lower among 11 FTM individuals. There were no differences in
ghrelin among the groups.
Body mass index and fat redistribution among transgender adults
Both transgender men andwomen experienced changes in body
mass index; Asscheman et al., 1989 observedminor weight gain and
weight loss for both FTM (n ¼ 122) and MTF (n ¼ 303) individuals
[47]. Within this study, only the FTM transgender individuals
experienced aweight gain of more than 10% of their bodyweight on
HT, and all 21 of these individuals were obese at the start of the
study.
Elbers et al. (1999) found increases in thigh muscle mass on MRI
among FTM (n¼17) individuals after 12months of hormone therapy
[55]. FTM individuals also had a decrease in overall subcutaneous fat
deposition, however they showed greater visceral fat deposition,
demonstrating fat redistribution. The reverse was true for MTF
individuals (n¼20) in the study,where imaging showed increases in
subcutaneous fat after 12 months of therapy but decreases in
visceral fat and thigh muscle mass. The study authors noted that
while hormone therapy is reported to cause fat redistribution, the
exact role of both testosterone and estrogen in weight is unclear.
Bone mass
Increased osteopenia in transgender women on HT
Studies with the greatest statistical power show increased rates
of osteopenia in transgender women on HT, however these may be
limited by including participants who used anti-androgens for one
year before starting estrogen therapy. Wierckx et al. (2012)examined 100 transgender men and women after a mean of 10
years on HT; 25% of transgender women experienced osteoporosis
whereas transgender men did not [6]. Decreased bone mass has
been reported at the lumbar spine [56], hip and radius regions [57].
There are a lack of fracture data available in transgender in-
dividuals. Wierckx et al. (2012) suggested that this decrease in bone
mass could be due to either increased screening of MTF individuals,
anti-androgen therapy itself (as noted in the decreased bone mass
of non-transgender men on anti-androgens), or prior clinical
practices of administering an anti-androgen for one year before the
start of estrogen therapy [6]. Additionally, transgender women in
Wierckx et al. (2012) had lower estrogen levels than female controls
which may account for their relative rise in osteopenia [6]. Mueller
et al. (2011) observed that among 84 MTF treated with estrogen
therapy there was no increased risk of osteoporosis. This group also
concluded that previous studies ﬁnding decreases in bone mass
were those that began anti-androgen therapy alone for the ﬁrst year
without concomitant use of estrogen [58]. Also supporting this
ﬁnding is Ruestche et al. (2005), who found that among 24 MTF
individuals, those who had decreased bone mass (n ¼ 5) were only
those noncompliant with their estrogen therapy [59].
Pituitary
There are reports of enlarged pituitary glands among MTF in-
dividuals on HT [60], as well as six case reports of prolactinoma
[61e64]. Prolactin levels have also been reported to be elevated
among MTF individuals during long-term HT [60].
Other considerations
Androgen deprivation in MTF individuals may decrease sexual
desire, FTM HT may increase it
Wierckx et al. (2014) used survey data to elucidate a self-
reported decrease in sexual desire among two-thirds of MTF
adults (n ¼ 214) and a self-reported increase in sexual desire
among two-thirds of FTM individuals (n ¼ 138) who had under-
gone either HT or gender conﬁrmation surgery [65]. Nevertheless,
an earlier study reported that while self-reported decreased sexual
desire was experienced in one-third of a group of 62 MTF in-
dividuals, this level was similar to a group of pre-menopausal fe-
male controls [66]. A subsequent study of MTF individuals with
self-reported decreased sexual desire began a testosterone patch
used to treat decreased sex drive in cisgender women. All subjects
found that their sexual desire improved without masculinizing
effects, and none of the transgender women discontinued the
testosterone [67].
Autoimmune conditions with a female prevalence in transgender
women on HT
There are two case reports of systemic lupus erythematosus
occurring in MTF individuals with no prior history of autoimmunity
deﬁcits; one case presented with SLE 1 year after starting estrogen
injections, and another after 20 years on HT [68,69].
Conclusions
Compiled evidence from this literature review suggests that HT
for transgender individuals is safe without a large risk of adverse
events when followed carefully for a few well-documented medical
concerns as follows. The primary concern amongMTF individuals on
estrogen therapy is the possibility of developing thrombogenic
complications [2e7]. Therefore, educating MTF individuals and their
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events might be the most important long-term assessment of
transgender women in order to minimize the risk of adverse effects
of HT. Suggested riskmodiﬁcations fromgroups studying VTE among
MTF individuals include addressing any hypercholesterolemia, hy-
pertension or smoking use that a patient might have. Hyper-
coaguable risk factors, including the use of a thrombogenic estrogen,
ethinyl estradiol, have been associated with many of the cases of
reported VTE, and as such the risk of these adverse events may
continue to decline as the usage of this drug diminishes [3]. Other
health outcomes for transgender women may include increased
triglycerides [48] and decreased sexual desire [65].
There aremultiple case reports of conditions associatedwithMTF
HT, including the incidence of meningiomas [43e45], benign pitui-
tary tumors and prolactinomas [61e65] alongwith the occurrence of
autoimmune conditions with a female predominance, such as sys-
temic lupus erythematosus [69,70]. However, the data are too
limited to make any type of conclusion or recommendation.
Transgender men did not experience the increase in thrombo-
genic complications that some transgenderwomen reported [2,4e6].
Both transgender men and women experienced an increase in
insulin resistance, fasting glucose and changes in body fat redis-
tribution [4,5,47,53,54]. Adipocyte-derived hormone levels may
reﬂect changes in insulin sensitivity on hormone therapy, as
transgender men had decreased adiponectin levels while trans-
gender women had decreased leptin, both associated with insulin
resistance [52,53].
Although modest, current research supports the view that there
is no signiﬁcant increase in cancer prevalence among transgender
individuals on HT [5,23,24,47]. The majority of research on the ef-
fect of testosterone speciﬁcally on female reproductive tissues may
suggest that there is no elevated risk for hyperplasia among FTM
individuals, however such a guideline is preliminary as research to-
date is contradictory [25e30].
Transgender individuals should also not exclude surveillance for
cancers unique to their natal sex; transgender women have pre-
sented with prostate cancer, and transgender menwith uterine and
cervical cancer [31e33,42]. Both MTF and FTM individuals have
presented with breast cancer [34e41].
The Standards of Care (SOC) released by the World Professional
Association for Transgender Health (WPATH) report that the
greatest risk factor of MTF HT to be VTE and increased triglycerides,
which is supported by this literature review [70]. The greatest risk
factor of FTM HT reported by WPATH SOC is polycythemia, which
differs slightly from the only very small increases of hematocrit
among transgender men observed in the literature on HT [69]. The
guidelines established by the Endocrine Treatment of Transsexual
Persons of the Endocrine Society are also supported by this litera-
ture review [71]. The seven suggested items to monitor listed
include screening for cancers of the sex assigned at birth, breast
cancer screening of MTF individuals, BMD tests, cardiovascular and
laboratory proﬁle monitoring, as well as the prolactin levels of MTF
individuals [71]. Finally, this review would also support caution for
patients with potential hormone sensitive conditions, with
contraindication to HT in the presence of cancers that are sensitive
to estrogen and testosterone [71]. This review would not support
the recent 2014 USA Food and Drug Administration (FDA)
requirement that testosterone products display a warning for the
risk of VTE, deep vein thrombosis and pulmonary embolism [72].
With the exception of a few large-cohort and long-term studies,
much of the existing knowledge about the health impact of trans-
gender HT is based on case reports. While these provide clues to
effects of transgender HT, there is a strong need for future research
of greater cohort size to be undertaken in order to address this
critical gap.Conﬂicts of interest
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Author’s note: In some instances, studies reviewed inappropri-
ately referred to MTF individuals as “transsexual men”, referred to
FTM individuals as “women”, or otherwise referred to transgender
individuals by their natal sex. These discrepancies were conﬁrmed
and corrected after communication with the original author of the
work or by further analyzing the manuscript. The deﬁnitions of
these terms as used in this paper are below.
FTM: female to male transgender, transgender man. FTM in-
dividuals are thosewhose natal sex is female, and transition to their
identiﬁed and lived male gender.
Gender conﬁrmation surgery e any surgery to alter function or
appearance of tissues from natal sex to sex of the individual’s
identiﬁed and lived gender identity.
Hormone therapy (HT): HT in this paper for FTM individuals
typically involves testosterone HT. HT for MTF individuals involves
estrogen and anti-androgens, such as spironolactone.
MTF: male to female transgender, transgender woman. MTF
individuals are thosewhose natal sex is male, and transition to their
identiﬁed and lived female gender.
Transgender e a term to describe an individual whose gender
identity is different than natal sex.References
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